Neuberg Diagnostics, one of India’s fastest-growing pathology and diagnostic chains, is preparing for an initial public offering (IPO) within the next six months. The company, which operates over 150 labs and 2,000+ collection centres across India and internationally, aims to capitalise on rising demand for advanced diagnostics, preventive health screening, and digital health integration amid increasing chronic disease prevalence and health awareness.
Glimpse:
Neuberg’s leadership confirmed IPO preparations are in advanced stages, with merchant bankers already appointed and regulatory filings expected soon. The offering will fund aggressive expansion into tier-2 and tier-3 cities, acquisition of regional labs, rollout of AI-powered diagnostic tools, and strengthening its genomics and molecular testing capabilities. The company reported strong revenue growth in FY25 and projects continued momentum driven by preventive care trends and government health initiatives.
Neuberg Diagnostics, the rapidly expanding pathology and diagnostic services provider headquartered in Ahmedabad, is gearing up for an initial public offering (IPO) within the next six months, according to senior management statements made during an industry briefing on January 23, 2026. The move comes at a time when India’s diagnostics sector is experiencing explosive growth, fuelled by rising chronic disease burden, increasing preventive health checkups, expanding insurance coverage, and growing demand for specialised testing such as genomics, molecular diagnostics, and AI-assisted pathology.
Neuberg currently operates more than 150 labs and over 2,000 collection centres across 10+ countries, including a strong presence in India, South Africa, UAE, and Nepal. The company offers a comprehensive menu of over 4,000 tests, ranging from routine biochemistry and haematology to advanced oncology, reproductive genetics, and infectious disease panels. It has built a reputation for accuracy, fast turnaround times, and digital-first services, including home collection, online report access, and integration with hospital systems.
The planned IPO will primarily fund organic and inorganic growth: establishing new state-of-the-art labs in underserved regions, acquiring smaller regional chains, investing in AI and automation for faster and more accurate reporting, and expanding genomics and precision diagnostics capabilities. Neuberg has already partnered with global technology providers and is rolling out AI tools for image analysis in histopathology and predictive risk scoring in preventive health packages.
Dr. GSK Velu, Founder and Chairman of Neuberg Diagnostics, said:
“The diagnostics sector is at an inflection point in India. With rising health awareness, increasing chronic disease prevalence, and supportive government policies, demand for quality, accessible testing is at an all-time high. An IPO will give us the capital and visibility to scale faster, invest in cutting-edge technology, and serve millions more patients across the country and beyond.”
The company has shown robust financial performance, with strong double-digit revenue growth in recent years and improving EBITDA margins driven by scale, operational efficiency, and a shift toward higher-margin specialised tests. Industry analysts expect the IPO to attract significant interest from institutional investors seeking exposure to India’s high-growth healthcare services space.
Neuberg’s IPO preparations come amid a wave of activity in India’s diagnostics sector, with several large chains pursuing public listings or strategic sales to capitalise on favourable market conditions and the long-term tailwinds of preventive health, ageing population, and digital integration under Ayushman Bharat.
“Diagnostics is the gateway to modern healthcare. As India moves toward preventive and precision medicine, we are positioning Neuberg to lead this transformation delivering faster, smarter, and more affordable insights to patients and doctors nationwide.”
By
HB Team
